Home › NDC Lookup › RxCUI directory › RxCUI 2744288

Selexipag 0.15 MG Oral Tablet [Uptravi] — RxCUI 2744288

RxNorm drug concept · Semantic branded drug
RxCUI 2744288 Semantic branded drug · SBD ● Current RxNorm concept 12 FDA products 13 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2744288
Official nameSelexipag 0.15 MG Oral Tablet [Uptravi]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asUptravi 0.15 MG Oral Tablet; Uptravi 150 MCG Oral Tablet
FDA products mapped12
Package NDCs mapped13
Reported Medicaid activity (SDUD)8,761 prescriptions · 34 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Selexipag: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Selexipag treats pulmonary arterial hypertension, a type of high blood pressure in the arteries of your lungs. It helps delay the disease getting worse and lowers the chance you'll...
  • Tablets are taken by mouth twice a day and swallowed whole, so don't split or crush them. Taking them with food may help you tolerate them. Your doctor will raise your dose slowly,...
  • Headache, diarrhea, nausea, jaw pain and muscle aches are common, especially while your dose is going up. Tell your doctor or pharmacist if they become hard to handle, since the do...
  • Call right away if you have new or worsening shortness of breath, which could be fluid in the lungs. Also report symptoms that might suggest an overactive thyroid, or signs of an a...
📖 Read our full Selexipag guide →

🕸️ Concept Web — How Selexipag 0.15 MG Oral Tablet [Uptravi] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Selexipag 0.15 MG Oral Tablet [Uptravi] RxCUI 2744288

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Selexipag 1729002
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Uptravi 1729008
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Selexipag Oral Tablet 1729006
    • Selexipag Oral Product 1729004
    • Selexipag Pill 1729005
    • Selexipag Oral Tablet [Uptravi] 1729010
    • Uptravi Oral Product 1729011
    • Uptravi Pill 1729012
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Selexipag 0.15 MG Oral Tablet SCD · 2744286
  • Selexipag 0.15 MG SCDC · 2744285
  • Selexipag Oral Tablet SCDF · 1729006
  • Selexipag Oral Product SCDG · 1729004
  • Selexipag Pill SCDG · 1729005

Brand-Name Concepts

  • Selexipag 0.15 MG [Uptravi] SBDC · 2744287
  • Selexipag Oral Tablet [Uptravi] SBDF · 1729010
  • Uptravi Oral Product SBDG · 1729011
  • Uptravi Pill SBDG · 1729012
  • Uptravi BN · 1729008

📦 FDA Products & Package NDCs

12 products · 13 package NDCs
13 package NDCs map to RxCUI 2744288 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
66215-0602-06 1 BOTTLE in 1 CARTON (66215-602-06) / 60 TABLET, COATED in... UPTRAVI Actelion Pharmaceuticals US, Inc. 2015-12-21
66215-0602-14 1 BOTTLE in 1 CARTON (66215-602-14) / 140 TABLET, COATED in... UPTRAVI Actelion Pharmaceuticals US, Inc. 2015-12-21
66215-0604-06 1 BOTTLE in 1 CARTON (66215-604-06) / 60 TABLET, COATED in... UPTRAVI Actelion Pharmaceuticals US, Inc. 2015-12-21
66215-0606-06 1 BOTTLE in 1 CARTON (66215-606-06) / 60 TABLET, COATED in... UPTRAVI Actelion Pharmaceuticals US, Inc. 2015-12-21
66215-0608-06 1 BOTTLE in 1 CARTON (66215-608-06) / 60 TABLET, COATED in... UPTRAVI Actelion Pharmaceuticals US, Inc. 2015-12-21
66215-0610-06 1 BOTTLE in 1 CARTON (66215-610-06) / 60 TABLET, COATED in... UPTRAVI Actelion Pharmaceuticals US, Inc. 2015-12-21
66215-0612-06 1 BOTTLE in 1 CARTON (66215-612-06) / 60 TABLET, COATED in... UPTRAVI Actelion Pharmaceuticals US, Inc. 2015-12-21
66215-0614-06 1 BOTTLE in 1 CARTON (66215-614-06) / 60 TABLET, COATED in... UPTRAVI Actelion Pharmaceuticals US, Inc. 2015-12-21
66215-0616-06 1 BOTTLE in 1 CARTON (66215-616-06) / 60 TABLET, COATED in... UPTRAVI Actelion Pharmaceuticals US, Inc. 2015-12-21
66215-0628-20 1 KIT in 1 CARTON (66215-628-20) * 1 BOTTLE in 1 CARTON /... UPTRAVI Titration Pack Actelion Pharmaceuticals US, Inc. 2015-12-21
66215-0718-01 1 VIAL, SINGLE-DOSE in 1 CARTON (66215-718-01) / 10 mL in 1... UPTRAVI Actelion Pharmaceuticals US, Inc. 2021-07-29
66215-0910-14 1 BOTTLE in 1 CARTON (66215-910-14) / 140 TABLET, FILM COAT... UPTRAVI Actelion Pharmaceuticals US, Inc. 2026-05-23
66215-0915-14 1 BOTTLE in 1 CARTON (66215-915-14) / 140 TABLET, FILM COAT... UPTRAVI Actelion Pharmaceuticals US, Inc. 2026-05-23
Observed labelers: Actelion Pharmaceuticals US, Inc. (13) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.